Porous orbital implant structure

• US 6,063,117 A
• Filed: 01/22/1998
• Issued: 05/16/2000
• Est. Priority Date: 01/22/1998
• Status: Expired due to Term

• Current Assignee: Arthur C. Perry
• Original Assignee: Arthur C. Perry
• Inventors: Perry, Arthur C.
• Primary Examiner(s): Mancene, Gene
• Assistant Examiner(s): Robert, Eduardo C.
• Application Number:
  US09/010,629
• Time in Patent Office: 845 Days
• Field of Search: 623/4, 623/11, 623/15, 433/173, 433/174
• US Class Current: 623/6.64
• CPC Class Codes: A61F 2/141 Artificial eyes
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 27/306 Other specific inorganic materials not covered by A61L27/303 - A61L27/32
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

A porous structure for implantation into the orbital cavity of a mammal who has had an ocular enucleation, evisceration or who needs to have an orbital implant replaced, the structure comprising pores having a mean size of less than 200 micrometers. Also disclosed is a surgical method for placing an implant into a mammal who has had an ocular enucleation, evisceration or who needs implant replacement, whereby the implant obtains rapid ingrowth of connective and vascular tissues. The method comprises: selecting a porous ocular implant comprising pores with a mean size of less than 200 micrometers; and, placing the implant into an orbital cavity of a mammal.

Claims

1. A non-polyethylene porous orbital implant structure for implantation into the orbital cavity of a mammal comprising pores having a mean size of less then 200 micrometers.

2. The porous structure of claim 1, wherein said structure comprises a ceramic.

3. The porous structure of claim 1, wherein said structure comprises hydroxyapatite.

4. The porous structure of claim 1, wherein said structure consists essentially of a ceramic.

5. The porous structure of claim 1, for implantation into the orbital cavity of a mammal comprising pores having a mean size of from 50 to 150 micrometers.

6. The porous structure of claim 5, for implantation into the orbital cavity of a mammal comprising pores having a mean size of from 60 to 90 micrometers.

7. The porous structure of claim 6, for implantation into the orbital cavity of a mammal comprising pores having a mean size of from 75 to 85 micrometers.

8. The porous structure of claim 7, for implantation into the orbital cavity of a mammal comprising pores having a mean size of about 77 micrometers.

9. The porous structure of claim 1 further comprising a growth factor.

10. The porous structure of claim 9, wherein the growth factor is recombinant human basic fibroblast growth factor beta.

11. The porous structure of claim 1 further comprising a biocompatible coating.

12. The porous structure of claim 11, wherein the coating is calcium sulfate, polylactic acid, polyglycolic acid, or animal tissue.

13. A surgical method for placing an implant into a mammal who has had an ocular enucleation, evisceration or who needs implant replacement, whereby the implant obtains rapid ingrowth of connective and vascular tissues, said method comprising:

selecting a non-polyethylene porous ocular implant comprising pores with a mean size of less than 200 micrometers; and

placing the implant into an orbital cavity of a mammal.

14. The method of claim 13, further comprising a step of burying the implant beneath conjunctival tissues of the mammal.

15. The method of claim 13 further, comprising a step of covering the implant before the placing step.

16. The method of claim 15, wherein the covering step comprises covering the implant with scleral tissue.

17. The method of claim 15, wherein the covering step comprises covering the implant with calcium sulfate, polylactic acid, polyglycolic acid or animal tissue.

18. The method of claim 13, further comprising applying a growth factor to the implant.

19. The method of claim 18, wherein the step of applying a growth factor comprises applying recombinant human basic fibroblast growth factor beta.